Gustavo Alva, MD, DFAPA

Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.

Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.

Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.

Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.

Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.

Carmen Kosicek, MSN, PMHNP-BC; Charles Montano, MD; and Gus Alva, MD, DFAPA, provide take-home messages for the management of patients with MDD and other depressive disorders.

Experts in psychiatry examine emerging agents and unmet needs for the management of MDD.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.

Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.

Experts in psychiatry share their treatment approaches for the management of episodic and chronic MDD.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, review currently available treatment options for the management of MDD and criteria used for treatment selection.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.

Experts in psychiatry share their thoughts on the perception of MDD within the healthcare community and the implications of this condition being viewed as chronic vs episodic.

Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.

Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.

Gus Alva, MD, DFAPA, discusses key takeaways for the management of bipolar disorder.

Dr. Gus Alva shares his initial impressions on this case and treatment approaches to bipolar 1 disorder.

Gus Alva, MD, DFAPA, presents the case of a 23-year-old female diagnosed with bipolar 1 disorder.

Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.

A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.

Michael E. Thase, MD, presents the case of a 47-year-old man with treatment resistant bipolar depression.

Psychiatric experts consider mood stabilizers when treating bipolar disorder and review the role of antidepressants in disease management.

Theresa Cerulli, MD, and Tina Matthew-Hayes, DNP, FNP, PMHNP, review diagnostic difficulties of the patient’s primary care physician in patient case #1 and share optimal approaches to the diagnosis and treatment for patients with bipolar disorder.

Tina Matthews-Hayes, DNP, FNP, PMHNP, comments on screening tools for bipolar disorder and Gustavo Alva, MD, DFAPA, shares his impressions from patient case #1.

A panel of experts in psychiatry share insights on the challenges and importance of making an accurate diagnosis of bipolar disorder.

Experts in psychiatry review the case of a 27-year-old woman who presents for evaluation of a complex depressive disorder.